Treatment combination1 | Mean disease incidence (%) at Teppi2 | Mean disease incidence (%) at Jimma2 | ||||||
---|---|---|---|---|---|---|---|---|
Local | Boziab | Local | Boziab | |||||
PDIi | PDIf | PDIi | PDIf | PDIi | PDIf | PDIi | PDIf | |
Control | 15.79a | 79.47a | 14.49a | 79.76a | 15.46a | 80.44a | 15.21a | 77.15c |
L | 9.65cd | 63.02d | 6.48f | 48.74g | 8.02ef | 52.75fg | 6.93ef | 51.07gh |
F | 11.91b | 58.88e | 9.64cd | 64.47d | 13.20bc | 64.45d | 11.73c | 63.60d |
S | 14.37a | 75.24b | 15.30a | 77.87a | 14.94a | 78.92ab | 14.40ab | 75.21bc |
L + F | 9.89c | 58.88e | 7.88ef | 64.48d | 7.86ef | 42.04k | 7.41ef | 46.96ij |
L + S | 9.41cd | 75.24b | 10.00c | 52.15f | 9.93d | 54.72ef | 8.33e | 47.90ij |
F + S | 14.70a | 69.44c | 9.60cd | 64.46d | 12.72c | 64.08d | 11.84c | 55.71e |
L + F + S | 8.25de | 49.03g | 7.40ef | 45.85h | 7.20ef | 46.61j | 6.44f | 49.75hi |
LSD (0.05) | Â | 2.19 | 1.02 | Â | ns | 2.81 | Â | Â |
CV (%) | Â | 2.20 | 7.84 | Â | 8.93 | 2.80 | Â | Â |